Learning healthcare systems rely on potentially sensitive data and biospecimens from patients who typically have no knowledge of secondary uses of these resources for research. While this failure to inform patients of these practices is consistent with human subject regulations for research, these practices risk controversy and a loss of trust in the integrity of healthcare institutions. This article reviews recent controversies in this domain and argues for new institutional practices that entail patient education about secondary uses of data and biospecimens and the opportunity for patient choice in the form of an opt-out system. This approach would enhance transparency and reduce the risk of a loss of public trust in the research enterprise. The advent of electronic health records makes this effort feasible, along with the existence of health systems that care for hundreds of thousands or millions of patients over time. While the prospects for substantial improvements in the quality of care are exciting, there are a host of challenges in obtaining meaning conclusions from these datasets. From an ethical perspective, a central issue is how to maintain the trust of patients and their families when sensitive data are being accessed and used for secondary purposes, that is, purposes beyond the welfare of the source individuals. While trust is not essential to acquiring data or to data analytics, trust is essential to any system that seeks to endure in this sensitive healthcare space. I will argue that 2 keys to deserving and maintaining trust are transparency about policies and practices, and an element of patient choice for secondary uses of data and biospecimens (DAB).
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The advent of electronic health records makes this effort feasible, along with the existence of health systems that care for hundreds of thousands or millions of patients over time. While the prospects for substantial improvements in the quality of care are exciting, there are a host of challenges in obtaining meaning conclusions from these datasets. From an ethical perspective, a central issue is how to maintain the trust of patients and their families when sensitive data are being accessed and used for secondary purposes, that is, purposes beyond the welfare of the source individuals. While trust is not essential to acquiring data or to data analytics, trust is essential to any system that seeks to endure in this sensitive healthcare space. I will argue that 2 keys to deserving and maintaining trust are transparency about policies and practices, and an element of patient choice for secondary uses of data and biospecimens (DAB).
In recent years, a substantial literature has grown on ethical and regulatory issues in the secondary uses of biospecimens and data for research purposes. 2, 3 For this chapter, I will not make a distinction between DAB for the simple reason that biospecimens are only useful if they are associated with data about the source individual (gender, diagnosis, treatment history, family history, racial group, etc) and biospecimens are only useful to create new data through the analysis of the sample. Further, I assume that the learning healthcare systems will seek to use biospecimens acquired in clinical care in basically the same fashion that data are used. I understand that some individuals and cultural traditions may view biospecimens differently than data because specimens are pieces of the physical body, but this distinction will only serve to support my arguments regarding transparency and choice. Further, I will not make a large distinction here between research and quality assurance (QA)/quality improvement uses of DAB. Although there has been much discussion of biobanks in other national and international contexts, my focus will be on the US system.
A core element of a learning healthcare system is the use of stored DAB obtained in clinical care from large numbers of individuals over time. Accordingly, the research uses of DAB are typically removed in time and space from the acquisition of these resources from the source individual. This gap leaves 3 options regarding traditional informed consent from patients. Consent might be obtained at the time of a clinical encounter for future, unspecified use of DAB. Second, individuals People can articulate general benefits, like improvements in health care, but often struggle with specifying risks or fears. A common concern from parents about research uses of newborn screening bloodspots was the prospect of cloning a baby. The protection of individual or family privacy is a major concern for many, particularly with research involving DNA analysis. 13 There is a prevalent belief that our DNA contains a host of personal information that is sensitive, creating risks of stigma or discrimination if not adequately protected.
While the fears associated with genetic research may be out of proportion to the true risk involved, these concerns are clearly legitimate. A more general, principle-based objection to research without permission arises from the sense for many that people "own" their biospecimens and respect demands that investigators seek permission for their use. 13 Other types of concerns may arise from cultural or religious traditions and historical experiences. As noted, the Havasupi case arose from objections to any research being conducted beyond the primary purpose of the DAB collection and from objections to the sensitive nature for their community of those particular projects. The rationale for requiring broad consent for biospecimen research was a perceived obligation to inform patients of this practice and to honor their autonomous choice. However, the NPRM in this respect was strongly opposed by the biomedical community. The concerns expressed from the research community were several fold. First, the consent document is relatively complex, meaning that a true informed consent would require a significant investment of time on the part of staff to talk through and explain the content. This would not be feasible as part of most routine clinical care where patients and staff are otherwise occupied with whatever health concerns brought the patient to the hospital or clinic. Admitting staff and clinicians are often not familiar with research practices using biospecimens so they would not be in a good position to obtain consent and respond to questions or concerns. Therefore, more than likely, consent forms would be presented as routine forms to sign and would be signed with cursory or no review, thus undermining the purpose of the consent process. Second, institutions would need to track the choices of each of the tens or hundreds of thousands of patients who obtain care in these facilities, choices that may change between visits, and assure that those choices were honored when investigators sought access to samples. This would be an extraordinary logistical challenge, likely requiring large financial investments in software and personnel to develop and maintain. Third, the lack of oversight for any research, once consent had been obtained, means that cases like the Havasupai Tribal case could occur again. That is, controversial or sensitive research could be conducted without any oversight from the institutions where patients sought their care. In summary, the criticism was that broad consent would be ineffective, highly complex, and expensive to institute and would not prevent abuses of trust by those choosing to seek care in these institutions.
Both the NPRM and the Newborn Screening Reauthorization Act illustrate discomfort at the level of the federal government with contemporary standards of consent for research with DAB. Surveys of public attitudes also consistently demonstrate a desire for greater engagement with patients about these practices. 13 The final regulations that emerged from the NPRM process were published in 45CFR46.116 7 A statement that the subject's biospecimens (even if identifiers are removed) may be used for commercial profit and whether the subject will or will not share in this commercial profit; … 9 For research involving biospecimens, whether the research will (if known) or might include whole genome sequencing (ie, sequencing of a human germline or somatic specimen with the intent to generate the genome or exome sequence of that specimen).
The new regulations also provide a provision for broad consent for secondary uses of biospecimens and data if the investigators wish to keep identifiers with the DAB and they do not wish to seek a waiver of consent. The requirements for broad consent are detailed and will be paraphrased here. These requirements are found at 45CFR46.116 (d) and are in addition to the standard requirements for informed consent:
(2) A general description of the types of research that might be conducted with the DAB. BOTKIN(3) A description of the DAB that might be used in research, whether sharing might occur, and the types of institutions with which sharing might occur.
(4) A description of the time period that DAB might be stored and might be used for research.
(5) Unless the subject will be provided details in specific research studies, a statement must be included that the subject will not be informed of details of the research, including its purpose and that they might have chosen not to consent to some of the specific research studies (6) A statement that all research results may not be disclosed to the subject
The purposes of these changes are several fold. As noted, the util- oversight by IRBs. In our own work, we found that most individuals simply assumed that clinical records were private and that residual clinical biospecimens were discarded as waste. 6 Accordingly, their awareness of a common, large-scale enterprise to use clinically acquired DAB in research comes as something of a shock and can engender concern and distrust. They may think, "If this is all so innocent, how come no one told me about it?" Trust by the general public in the research enterprise can be lost even when investigators, sponsors, and institutions are playing by the rules.
The challenge in this context is to strike the right balance given, on the one hand, the value of secondary uses of DAB to science and health care, and, on the other hand, the sensitivity many members of the public have over these practices. For the reasons discussed, a required informed consent process for all patients for such secondary uses is highly likely to be ineffective in acquiring autonomous authorization, burdensome to institutions, and damaging to the research enterprise. This damage is not primarily due to a large proportion of people declining access to their DAB but to an inability of hospital staff to effectively obtain and record consent during busy clinical services.
An appropriate compromise for learning healthcare institutions is a policy of notice and opt-out. The basic concept is that patients at learning healthcare institutions would be routinely informed about institutional policies regarding secondary uses of DAB for research purposes. For those patients who objected to such uses, they could choose to opt-out, precluding use of their DAB for research purposes.
The advantage of this approach is that it meets the expectations of many in the general public for 2 elements-they want to be told about what happens with their DAB and they want a choice over secondary uses.
The ethical justification for a notice and opt-out approach builds on the work of Miller and Wertheimer who developed a "fair transaction model for informed consent. 14 They argue that "The criteria for assessing the validity of consent transactions should be based on fair terms of cooperation for the respective parties that reflect the context of the activity for which consent is given." A fair process is one that is fair for both the subject of research and the investigator. Accordingly, high-risk research requires a high level of autonomous authorization by participants and low-risk trials require only limited level of authorization, or perhaps no authorization at all. In the context of learning healthcare systems, risks to patients are extremely low for secondary uses of DAB yet we know that when asked, they wish to provide some level of authorization for these practices. A policy of notice and optout arguably achieves fairness for both parties in that, for patients, they are offered information and choice and, for investigators and institutions, the effort would not unduly burden the clinical or research enterprises. We know from other contexts where notice and opt-out are offered, the large majority of individuals do not choose to opt-out, thus maintaining the integrity of the research resource for valuable studies.
There are a variety of considerations and challenges in making a notice and opt-out system ethically justifiable and functional. The notice would present information about the institutional practice regarding secondary uses of DAB and the safeguards in place to protect privacy and confidentiality. The disclosure could take many forms, but it must be sufficiently robust to count as a good-faith effort to inform people. If the notice is buried in another lengthy document, then it would be routinely overlooked by virtually everyone. This sort of disclosure might meet the legal interests of the institution in having offered notice, but it would not represent a good-faith effort at communication and transparency. So the notice needs to be in plain language, whether presented on paper or by audiovisual media, and offered in a place that welcomes the patient's attention. We also know that a large proportion of people are not very interested in these issues, particularly when they have other healthcare concerns that brought them to the hospital or clinic. But a small proportion of the population will be interested. To accommodate the variable levels of interest that different people will have, it would be ideal to offer the notice in a layered form. By this, I mean people would be able to dig deeper into the subject if they are interested. The basic notice could be short and simple, but those who want more information would be able to acquire that readily. This sort of layered document can be effectively supported through digital media. One possibility would be to send the notice to patients via email when they make an appointment, and once a year or so thereafter. The disclosure could be in a format that enables people to follow links to a more detailed set of information or resources about the policies and practices of their learning healthcare institutions, if they so wish.
Similarly, the ability to opt-out should not be burdensome. For example, requiring people to call an administrative office at the institution during limited hours of the week would effectively preclude the ability of all but the most motivated person to effectuate their choice.
However, given the value of DAB to learning healthcare institutions and the public's health, it may be appropriate to establish some minor barriers to record a decision to opt-out, such as a required review of the notice. A minor barrier will encourage people to give the issue some thought and have at least a minimal level of motivation to enact their choice.
The notice and opt-out approach is certainly consistent with the traditional and new federal regulations that actually require no disclosure or choice for secondary uses of DAB. As noted, the traditional approach is strongly supported by the biomedical community and is supported many ethicists and policy makers due to its value and demonstrated safety. We have found in our research with the general community that notice and opt-out is an acceptable institutional policy when people have a broader understanding of the issues and tradeoffs involved. 6 More direct evidence of the value of this approach comes from the experience at Vanderbilt University with the creation of their BioVU biobank. 15 The BioVU is a collection of biospecimens from residual blood obtained from patients at Vanderbilt that are linked to their electronic medical records. BioVU has a complex encryption system that permits the specimens to be deidentified to investigators while maintaining a longitudinal link with the electronic medical records so that specimen analysis can be informed by changes in clinical status of the patient. Until recently, BioVU used an opt-out model in which patients reinformed of the secondary uses of biospecimens and clinical records and they can opt-out of such uses.
Vanderbilt did extensive community engagement prior to launching the BioVU and found that greater than 90% of those surveyed supported the opt-out approach. 16 During the period of time when BioVU was using the opt-out approach, those choosing to opt-out were about 15% of patients, a number that is sufficiently robust to indicate that many patients were aware of their options. 17 The BioVU changed to an opt-in model when the National Institutes of Health adopted a policy requiring consent for the posting of sequence data on a publically accessible database, dbGaP. 18 Therefore, Vanderbilt moved away from the opt-out model not because the system was not working well but because of external requirements by the National Institutes of Health.
Research and the experience of projects like BioVU indicate that the notice and opt-out approach is feasible and can promote a high level of participation while promoting transparency and giving patients meaningful choice. Of course, implementing a notice and opt-out in learning healthcare systems for secondary uses of data and tissues for research and QA/quality improvement would not be easy.
Communication tools and systems for effective notice and choice need to be designed, tested, and implemented. Data documenting patient choice can be associated with the biospecimen or otherwise available in a dataset that can be accessed prior to research use. This is not a trivial task but presumably effective and efficient informatics approaches will become commonplace in learning healthcare systems.
Further, a simple opt-out system as described will not meet the needs of individuals with low literacy, cognitive or sensory impairments, or language barriers. These circumstances pose obstacles to any form of consent or engagement yet additional thought and resources are needed to address these challenges in this context. Beyond communication and choice for individuals, there are opportunities for transparency and engagement at the institutional level. Increasingly, patients and the lay public are being involved as partners in the design and conduct of research projects and resources such as biobanks. 18 These efforts and expenses are justifiable because they meet the clearly documented expectations of the public for the management of potentially sensitive DAB. Meeting public expectations for transparency and choice will maintain trust in our institutions in this new era of largescale data and tissue analysis.
